Birth outcomes after inadvertent use of category x drugs contraindicated in pregnancy: Where is the real risk?

Simple item page
dc.contributor.authorÖztürk Z.
dc.contributor.authorÖlmez E.
dc.contributor.authorGürpınar T.
dc.contributor.authorVural K.
dc.date.accessioned2024-07-22T08:10:11Z
dc.date.available2024-07-22T08:10:11Z
dc.date.issued2018
dc.description.abstractDrugs contraindicated in pregnancy are medicines that should be avoided by pregnant women, since they carry a concern for teratogenicity or there is no indication for their use during pregnancy. It does not mean that exposures to these drugs always cause harm. The aim of the present study was to investigate the risk of adverse outcomes following maternal exposure to the drugs contraindicated in pregnancy. We retrospectively analyzed prenatal drug exposure records of the pregnant patients referred to the clinical pharmacology consultation service in a tertiary-level university hospital from January 2007 until December 2012. Exposures to category X drugs (CXD) contraindicated in pregnancy were evaluated. After the expected date of delivery, we collected data about pregnancy complications and the outcomes. For comparison the women in the exposed group (N=52) were matched with a control group (N=162) of pregnant women without teratogenic exposure. We observed only one baby born with a birth defect (congenital cryptorchidism) in CXD group (2.6%) and four in control group (RR 0.91; 95% CI 0.10-7.94). The rates of adverse pregnancy outcomes including miscarriage, preterm birth and congenital abnormality were not significantly different from controls. However, the rate of elective termination of pregnancy was higher in women exposed to CXD while pregnant (RR 2.54; 95% CI 1.11-5.80, p = 0.027). Contraceptive failure and unintended pregnancy are the reasons for inadvertent drug exposure and choosing abortion. The high perception of teratogenic risk among pregnant women may cause terminations of pregnancies. Individual risk assessment and avoiding the phrase ‘CXD’ or ‘contraindicated in pregnancy’ in counseling may help to reduce maternal concerns about medication use in pregnancy. © 2018, Turkish Journal of Pediatrics. All rights reserved.
dc.identifier.DOI-ID10.24953/turkjped.2018.03.010
dc.identifier.issn00414301
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15118
dc.language.isoEnglish
dc.publisherTurkish Journal of Pediatrics
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAdolescent
dc.subjectAdult
dc.subjectContraindications, Drug
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant, Newborn
dc.subjectMiddle Aged
dc.subjectPregnancy
dc.subjectPregnancy Complications
dc.subjectPregnancy Outcome
dc.subjectPrenatal Exposure Delayed Effects
dc.subjectRetrospective Studies
dc.subjectRisk
dc.subjectTurkey
dc.subjectYoung Adult
dc.subjectatorvastatin
dc.subjectdesogestrel plus ethinylestradiol
dc.subjectdrospirenone plus ethinylestradiol
dc.subjectergotamine
dc.subjectestradiol benzoate plus progesterone
dc.subjectestradiol valerate plus norethisterone
dc.subjectethinylestradiol plus levonorgestrel
dc.subjectethinylestradiol plus norgestrel
dc.subjectetretin
dc.subjectisotretinoin
dc.subjectmedroxyprogesterone acetate
dc.subjectmisoprostol
dc.subjectacne
dc.subjectadult
dc.subjectalcohol consumption
dc.subjectamenorrhea
dc.subjectArticle
dc.subjectclinical pharmacology
dc.subjectcongenital malformation
dc.subjectcontrolled study
dc.subjectcryptorchism
dc.subjectdrug contraindication
dc.subjectfemale
dc.subjectfetus outcome
dc.subjecthormonal contraception
dc.subjecthuman
dc.subjecthyperlipidemia
dc.subjectlive birth
dc.subjectmajor clinical study
dc.subjectmaternal age
dc.subjectmaternal exposure
dc.subjectmiddle aged
dc.subjectmigraine
dc.subjectpregnancy complication
dc.subjectpregnancy outcome
dc.subjectpremature labor
dc.subjectretrospective study
dc.subjectrisk assessment
dc.subjectrisk factor
dc.subjectsmoking
dc.subjectspontaneous abortion
dc.subjecttelephone interview
dc.subjectadolescent
dc.subjectdrug contraindication
dc.subjectnewborn
dc.subjectpregnancy
dc.subjectpregnancy complication
dc.subjectpregnancy outcome
dc.subjectprenatal exposure
dc.subjectrisk
dc.subjectturkey (bird)
dc.subjectyoung adult
dc.titleBirth outcomes after inadvertent use of category x drugs contraindicated in pregnancy: Where is the real risk?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu